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Abstract
Background: Standard treatment for osteosarcoma patients consists of a combination of cisplatin, adriamycin, and
methotrexate before surgical resection of the primary tumour, followed by postoperative chemotherapy including
vincristine and cyclophosphamide. Unfortunately, many patients still relapse or suffer adverse events. We examined
whether common germline polymorphisms in chemotherapeutic transporter and metabolic pathway genes of the drugs
used in standard osteosarcoma treatment may predict treatment response.
Methodology/Principal Findings: In this study we screened 102 osteosarcoma patients for 346 Single Nucleotide
Polymorphisms (SNPs) and 2 Copy Number Variants (CNVs) in 24 genes involved in the metabolism or transport of cisplatin,
adriamycin, methotrexate, vincristine, and cyclophosphamide. We studied the association of the genotypes with tumour
response and overall survival. We found that four SNPs in two ATP-binding cassette genes were significantly associated with
overall survival: rs4148416 in ABCC3 (per-allele HR = 8.14, 95%CI = 2.73-20.2, p-value= 5.161025), and three SNPs in ABCB1,
rs4148737 (per-allele HR = 3.66, 95%CI = 1.85–6.11, p-value= 6.961025), rs1128503 and rs10276036 (r2 = 1, per-allele
HR = 0.24, 95%CI = 0.11–0.47 p-value= 7.961025). Associations with these SNPs remained statistically significant after
correction for multiple testing (all corrected p-values [permutation test] #0.03).
Conclusions: Our findings suggest that these polymorphisms may affect osteosarcoma treatment efficacy. If these
associations are independently validated, these variants could be used as genetic predictors of clinical outcome in the
treatment of osteosarcoma, helping in the design of individualized therapy.
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Introduction
Osteosarcoma is the most frequent malignant bone tumour in
children and adolescents. Standard treatment of osteosarcoma is
based on a combination of different drugs: neoadjuvant therapy
with methotrexate, cisplatin, and adriamycin followed by surgery
and post-operative chemotherapy (methotrexate, cisplatin, adria-
mycin, cyclophosphamide, and vincristine). Despite this, approx-
imately 30% of patients relapse or develop metastasis [1].
Clinical response to chemotherapeutics is a complex trait that
is influenced by genetic and environmental factors. Antican-
cer therapies have a narrow therapeutic range so that a
higher concentration in the patient’s body causes toxicity and a
lower concentration reduces the efficacy of the drug. Interindivi-
dual differences in pharmacokinetics and pharmacodynamics
determine the global response and toxicity profile of each drug.
In this process, the genes involved are the ones that control drug
absorption, distribution, metabolism, and excretion. The
majority of metabolism reactions are catalyzed by the cyto-
chrome P450 (CYP) enzymes [2]. Many chemotherapeutic
agents are also metabolized by glutathione S-transferases
(GSTs), phase II detoxification enzymes that catalyse the
conjugation of glutathione (GSH) to a wide variety of
xenobiotics [3]. Two types of transport superfamilies, ATP-
binding cassette (ABC proteins) [4] efflux pumps and solute-
linked carrier (SLC) influx proteins [5] are responsible for the
majority of drug transport [6]. Most of the drug metabolizers
and transporters contain many genetic polymorphisms, which
might cause large interindividual variability in the plasma
concentration of drugs.
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Pharmacogenetic studies have shown that germline polymor-
phisms in genes related to drug metabolism and transport can
have a major effect on the pharmacokinetics and pharmacody-
namics of these drugs [6]. We previously performed a study of the
nucleotide excision DNA repair pathway in relation to response to
cisplatin and observed an association between osteosarcoma
outcome and a polymorphism in ERCC2 gene [7]. Nevertheless,
a large portion of the interindividual variability in therapeutic
response remains unexplained.
Since mechanisms of transport and metabolism are shared
between drugs, genetic variation could affect the bioavailability of
more than one drug when they are used in combination, thus
affecting the global response to treatment or causing adverse drug
events. To address this, pharmacogenetic studies will need to focus
on integration of multiple drug pathways to allow a more complete
analysis of genetic factors influencing drug efficacy and toxicity.
In the current study, we studied a comprehensive set of SNPs
and CNVs that characterize the genetic variation of the multiple
metabolic and transport pathways of drugs used in osteosarcoma
treatment and their association with drug response.
Methods
Patients, treatments, and clinical variables
One hundred and two consecutive patients diagnosed with
osteosarcoma at the University Clinic of Navarra, Pamplona,
Spain, between 1986 and 2009 were enrolled in this study. All
samples were obtained with written informed consent from
patients, their parents, or both. Ethical approval of the study
was granted by the Ethics Committee of the University Clinic.
Patients were treated preoperatively with intravenous (i.v.)
adriamycin (3 courses at 25–30 mg/m2/day for 3 days), i.v.
methotrexate (4 courses of up to 14 g/m2/day for 1 day) and
intra-arterial cisplatin (3 courses at 35 mg/m2/day for 3 days).
After surgery, the adjuvant chemotherapy included methotrexate
(10 g/m2/day for 1 day and folinic acid rescue) and alternate
cycles of i.v. cisplatin/adriamycin or i.v. actinomycin D (0.45 mg/
m2/day for 3 days), cyclophosphamide (500 mg/m2/day for 3
days), and vincristine (1.5 mg/m2/day for 1 day) for up to 48
weeks of treatment.
Response to treatment was determined histologically as the
percentage of necrosis induced in the tumour after neoadjuvant
chemotherapy. Patients with less than 90% necrosis were classified
as poor responders and those with 90% necrosis or more, as good
responders [8]. Overall survival was considered as the time from
tumour diagnosis to death. Event-free-survival (EFS) was consid-
ered as the time from tumour diagnosis to the first of disease
recurrence, development of lung or bone metastases, and/or
death. Patients who were alive at the last follow-up evaluation
(January, 2010) were censored at that time. Other clinical data
including age, sex, tumour location, metastatic events (both at
diagnosis and during follow-up) and relapses (disease recurrence in
the same bone) were systematically recorded from the clinical
records. Only conventional high-grade osteosarcomas were
included, regardless of metastatic stage at diagnosis.
DNA extraction and quantification
Genomic DNAwas extracted from peripheral blood lymphocytes
using standard phenol-chloroform extraction protocols. DNA was
quantified using PicoGreen (Invitrogen Corp., Carlsbad, CA).
Candidate genes and selection of polymorphisms
A total of 24 candidate genes reported to be involved in the
metabolism or influx/efflux of the five drugs (cisplatin, adriamycin,
methotrexate, vincristine, and cyclophosphamide) were selected,
based on the information available in the Pharmacogenomics
Knowledge database PharmaGKB (www.pharmgkb.com). These
genes encode the following proteins:
Transporters: ABCA3, ABCB1, ABCC1, ABCC2, ABCC3,
ABCC4, ABCG2, ABCC6, SLC31A1, SLCO6A1, SLC19A1;
Phase I metabolism enzymes: MPO, SOD1, ALDH1A1, CYP3A4,
3A5, 2A6, 2B6, 2C8, 2C19, 2C9;
Phase II metabolism enzymes: GSTM1, GSTP1 and GSTT1.
SNPs were selected across all these genes except for the GSTT1
gene. CNVs were studied in the GSTT1 and GSTM1 genes.
TagSNPs for the selected genes were defined using Haploview
software v.4.0 (http://www.broad.mit.edu/mpg/haploview) with
an r2 threshold of 0.8 and a minimum minor allele frequency of
0.05. All defined tagSNPs were selected for possible genotyping
except those in the ABCC4 gene, for which an excessively elevated
number of tagSNPs was defined and so a subset of 57 of these were
selected.
In addition, both SNPs with potentially functional effects
(causing amino acid changes, potentially causing alternative
splicing, in the promoter region, in putative transcription factor
binding sites, or disrupting miRNAs and their targets) identified
using the bioinformatics tool PupaSuite (http://bioinfo.cipf.es/
pupasuite/www/index.jsp), and other functional SNPs already
described in the literature were selected.
This preliminary list of SNPs was filtered using as criteria
suitability for the Illumina genotyping platform (selecting only
those with an assay score.0.6, associated with a high success rate)
and minor allele frequencies (MAFs) of at least 5%.
A final number of 366 SNPs relevant to this study was included
in an oligonucleotide pool assay for analysis using the Illumina
Veracode technology (Illumina Inc., San Diego, CA).
SNP Genotyping
300 ng of DNA for each sample were genotyped using the
GoldenGate Genotyping Assay with Veracode technology accord-
ing to the published Illumina protocol. Data were analysed with
GenomeStudio software for genotype clustering and calling. We
excluded from further analysis SNPs with a call rate ,0.95 and
SNPs that deviated from Hardy-Weinberg equilibrium.
Duplicate samples and CEPH trios (Coriell Cell Repository,
Camden, NJ) were genotyped across the plates. SNPs showing
Mendelian allele-transmission errors or showing discordant
genotypes were excluded from the analysis.
GSTM1 and GSTT1 copy number assays
GSTT1 and GSTM1 copy number was calculated using Taqman
Copy Number Assays (Hs00010004_cn probe for GSTT1 and
Hs02575461_cn for GSTM1, Applied Biosystems, Foster City, CA)
following the manufacturer’s protocol on an ABI PRISM 7900
Sequence Detection System (Applied Biosystems). RNAse P was
used as the reference in TaqMan Copy Number Reference Assays.
Data were analyzed using absolute quantification of resulting Ct
values generated on the sequence detection system. Copy number
was estimated using the CopyCaller 1.0 software (Applied
Biosystems). Each sample was evaluated in triplicate.
Statistical analysis
Associations between tumour response and genotypes was
assessed using logistic regression analysis [9], comparing genotype
frequencies in poor responders versus good responders and
estimating odds ratios (OR). Homozygotes for the most frequent
allele were used as the reference group. SNPs were also assessed in
relation to overall survival and event free survival (EFS) using Cox
A Pharmacogenetic Study on Osteosarcoma Treatment
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regression analysis [10]. Metastasis at diagnosis (no, yes) was
included as covariate in multivariable logistic regression and Cox
regression analyses.
A permutation test was used to estimate p-values corrected for
multiple testing. Each replicate consisted of randomly assigning
the set of three variables, response to treatment, survival status and
analysis time, across subjects and then carrying out the association
analyses for each of the 348 successfully genotyped variants and
each of the two outcomes (response to treatment and survival).
The minimum p-value of these 696 ( = 34862) tests was then
recorded. Ten thousand such replicates were carried out and the
corrected p-values were estimated as the proportion of replicate p-
values less than the corresponding unadjusted p-value. Reported p-
values are uncorrected for multiple testing, unless otherwise stated.
Only SNP associations with corrected p-values ,0.05 were
considered statistically significant.
Haplotypes containing rs1045642, rs2032582 and rs1128503 in
ABCB1 were inferred by PHASE software, version 2.0. Association
with overall survival was then assessed using Cox-regression
analysis. Kaplan-Meier curves were generated using SPSS (version
15.0, SPSS Inc., Chicago, IL, USA). All other analyses were
carried out using PLINK or R (version 2.6.0.2).
Results
Patients
The main clinical data for the 102 osteosarcoma patients are
presented in Table 1. The median age at diagnosis was 14 years
(range 3 to 34 years). At the time of diagnosis, 21% of the patients
already presented metastasis, while 22% developed metastasis
during follow-up. The median follow-up time was 231 months
(range 3–303).
Response to treatment (necrosis) data were available for 91
patients and overall survival data were available for 101 patients.
The percentage of good responders to therapy was 54 and the
median overall survival was 219 months.
Of the clinical variables analyzed, metastasis at diagnosis was
found to be associated with increased risk of death (HR=2.92,
95%CI= 1.35–6.28, p-value=0.006).
Association between polymorphisms and clinical data
A total of 346 SNPs out of 366 and two CNVs were successfully
analyzed. Eleven patients were removed for low genotyping call
rate (,95%), so finally 91 patients were successfully analyzed.
Results from the analysis of overall survival are presented in
Table 1 and Figure 1. We identified four SNPs (two of them in
complete linkage disequilibrium) in two genes that were associated
with overall survival. The T allele of the synonymous SNP
rs4148416 (G1013G) in the ABCC3 gene was associated with
higher risk of death (per-allele HR=8.14, 95%CI= 2.73–20.2, p-
value=5.161025, Figure 1A). In particular, the estimated five-year
survival rate for patients carrying the CC genotype of rs4148416
was 78% compared to 20% for heterozygous patients.
The G allele of s4148737, an intronic SNP located in the
ABCB1 gene, was associated with poorer overall survival (per-allele
HR=3.66, 95%CI= 1.85–6.11, p-value=6.961025,) Figure 1B).
The estimated five-year survival rate for patients carrying the
common AA genotype was 93% compared to 38% for patients
homozygous for the G allele. The minor alleles of two other SNPs
(rs1128503 and rs10276036) in this gene, in complete linkage
disequilibrium (LD, r2 = 1.0), and in partial LD with rs4148737
(r2 = 0.48), were also associated with better overall survival
(per-allele HR=0.24, 95%CI=0.11–0.47, p-value=7.961025,
Figure 1C). For these two SNPs, the estimated five-year survival
rate for common homozygotes was 49% compared to 100% for
patients homozygous for the rare allele. These results did not
change substantially after adjusting for metastasis at diagnosis
(Table 2). All three associations remained statistically significant
after correction for multiple testing (corrected p-value#0.030).
We also studied these SNPs in relation to event-free survival
(EFS) and highly consistent results were observed (Table 2). None
of the SNPs analyzed were significantly associated with tumour
response after correction for multiple testing.
A combination of three SNPs located in ABCB1 (rs1045642 /
rs2032582/ rs1128503) was previously described as putatively
functional in several studies [4],[11],[12]. We explored whether
there is a haplotype formed by these three SNPs that is more
significantly associated with survival in these patients. We observed
two frequent haplotypes, one formed by the combination of the
three common alleles (CGC) with a frequency of 0.47 and the
other comprising the three rare alleles (TTT) with a frequency of
0.39. Considering CGC as reference, the TTT haplotype was
associated with better survival (HR=0.31, 95%CI=0.15–0.62, p-
value=0.001). The other haplotypes observed had lower frequency
and were not statistically significantly associated with survival.
Nevertheless, the estimated HR for the two haplotypes containing
the rare T allele in rs1128503 (CGT and CTT) were consistent
with it having a protective effect (HR=0.38 and 9.7861026,
respectively) in contrast with the other two haplotypes containing
the C wild-type allele (TGC and TTC; HR=1.26 and 1.95,
Table 1. Clinical characteristics of osteosarcoma patients
(N= 102).
Patients
N %
Age at diagnosis (years)
Median 14.8
Range 3–34
Sex
Female 45 44.1
Male 57 55.9
Location
Femur 51 50.0
Tibia 38 37.3
Arm 7 6.9
Central 6 5.9
Response to treatment
Good 52 57.1
Poor 39 42.9
Metastasis
No 59 57.8
At diagnosis 21 20.6
At follow up 22 21.6
Status
Alive 72 71.3
Dead 29 28.7
Relapse
No 85 83.3
Yes 17 16.7
doi:10.1371/journal.pone.0026091.t001
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respectively). These results suggested that the haplotypes were no
more informative than the rs1128503 SNP alone.
Regarding the CNVs analyzed, genotype data for GSTM1 and
GSTT1 were available for 98 and 99 patients, respectively. The
frequency of the homozygous gene deletion was 52% (51 patients)
for GSTM1 and 19% (19 patients) for GSTT1. There was no
evidence that either of these two polymorphisms were associated
with any of the clinical outcomes considered.
Discussion
This study assessed 346 SNPs and 2 CNVs in 24 key genes
involved in platinum, adriamycin, methotrexate, vincristine, and
cyclophosphamide pathways, and is the most comprehensive
pharmacogenetic study in osteosarcoma patients to date.
The use of large scale genotyping methods to screen multiple
drug pathways has allowed us to identify four SNPs (two of them in
total LD) that are highly associated with overall survival and that
might be useful prognostic markers in these patients.
To our knowledge, the majority of the pharmacogenetic studies
are biased towards candidate polymorphisms in pharmacogenetic
genes already described as functional in previously published data.
However, given the complexity and the lack of understanding of
both genetic variation effects and regulation of chemotherapy
action, these polymorphisms explain only a portion of the
observed phenotypic variability in the drug outcome. In our
study, we have assessed all genes well-known to be involved in the
metabolism and transport pathways of the drugs used in
osteosarcoma treatment. In order to avoid any bias, we selected
not only already described and potentially functional polymor-
phisms, but also tagSNPs, to obtain a more comprehensive view
and to detect novel markers that could play a role in the
interindividual differences observed of outcome risk in osteosar-
coma patients.
ABCC3 is a member of the multidrug resistance protein (MRP)
family and is expressed in liver, gallbladder, kidney, and gut
[13],[14]. Main substrates of ABCC3 are bile salts [15], but it also
transports anticancer drugs, among which methotrexate [16],
[17]. Vincristine, doxorubicin, and cisplatin have also been
suggested to be ABCC3 substrates, but there are no clear results
[17], [18]. The expression of ABCC3 mRNA has been related to
drug resistance [16] but to date only limited studies have been
published studying polymorphisms in ABCC3. Only promoter
SNPs and non-synonymous SNPs have been investigated as
potentially functional variants [19,20], but, to our knowledge,
there are no studies showing association between these genetic
ABCC3 variants and survival after treatment in cancer patients. In
the present study we found that SNP rs4148416 in this gene was
associated with an 8-fold risk of low survival and this is the first
evidence of its clinical relevance. This SNP leads to a synonymous
change (G1013G) at exon 22. The other SNPs we found associated
with osteosarcoma survival are located in the ABCB1 gene. This
gene is well-known and encodes a P-glycoprotein, an ATP-driven
efflux pump, that is overexpressed in many tumours and confers
multidrug resistance [21]. Of the drugs administered to these
patients, both doxorubicin and vincristine are transported by this
pump [22]. There are three variants in LD that have been studied
in detail: 2677G.T/A (rs2032582), 3435C.T (rs1045642) and
Figure 1. Kaplan-Meier survival curves for osteosarcoma
patients according to genotype for (A) rs4148416 in ABCC3
(X2 = 21.4, p-value = 3.861026); (B) rs4148737 in ABCB1
(X2 = 18.4, p-value = 1.061024); and (C) rs1128503 or
rs10276036 in ABCB1 (X2 = 20.9, p-value= 2.961025).
doi:10.1371/journal.pone.0026091.g001
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1236C.T (rs1128503). The first is a non-synonymous change,
while the other two are synonymous. These three SNPs have been
studied both individually and as a haplotype, but the results have
been inconsistent [4] [23] [11] [24]. The rare allele of rs1045642
has been reported to be associated with reduced P-glycoprotein
activity, both alone and in combination with the rare alleles of
rs2032582 and rs1128503 [23], [25]. These latter two variants
have also been reported to have independent functional effects in
different studies [12], [25], [26], [27]. However, it is still not clear
which is/are the functional variant/s in this gene.
In our study, of these three variants, only 1236T.C
(rs1128503) was strongly associated with survival in our series of
patients. This SNP leads to a synonymous change at residue 412 of
the protein and is well-known but there is no clear consensus on
its functional significance [28]. Some studies found increased
response in the presence of the T allele [29], [30] while others
found the opposite [31], or no genetic effect [32]. In our study, the
T allele was associated with increased survival. To see if the
association found was due to this single variant or to a
combination of the three already described polymorphisms we
also analyzed the effect of the haplotypes on overall survival. The
results were consistent with a single main effect for rs1128503.
Consistent results were reported by Balcerczak and colleagues in
colorectal cancer patients [12].
We found another SNP, rs10276036, associated with survival
that was in complete LD with the previous one. It is located in
intron 9 and has been linked with reduced area under the curve
(AUC) of SN-38, the active metabolite of CPT-11, [33]; however
its functional significance is unknown. The effect observed could
be explained by its correlation with rs1128503, rather than by
rs10276036 itself. Apart from the already described SNPs, we
found a polymorphism located in intron 17 (rs4148737) also
strongly associated with survival. This SNP was in low LD with the
other two SNPs. Further functional studies are needed to elucidate
which is the causal variant in the ABCB1 gene.
We hypothesize that the variants associated with overall survival
could have an effect on the efflux of the drugs used in the
treatment of osteosarcoma, thus impairing the response to the
treatment and therefore the overall survival. Although we did not
find a statistical association between these variants and tumour
response, this could be explained by the fact that tumour response
is evaluated after neoadjuvant therapy and at this point patients
have been treated exclusively with methotrexate, cisplatin, and
adriamycin. Therefore, the tumour necrosis data does not evaluate
Table 2. Genes and polymorphisms associated with overall survival (OS) and event free survival (EFS).
SNP Genotype N 5-year OS HR* OS Adjusted**HR EFS HR
survival rate (95%CI) (95%CI) (95%CI)
P-value P-value P-value
ABCC3
rs4148416 CC 85 78%
CT 5 20%
per allele T 8.14 7.25 6.33
(2.73–20.2) (2.62–20.1) (1.79–12.7)
0.000051 0.00014 0.00028
ABCB1
rs4148737 AA 28 93%
AG 49 75%
GG 13 38%
per allele G 3.66 2.83 2.60
(1.85–6.11) (1.56–5.12) (1.24–3.22)
0.000069 0.00061 0.00051
rs1128503 CC 26 49%
CT 50 82%
TT 14 100%
per allele T 0.24 0.27 0.42
(0.11–0.47) (0.13–0.54) (0.29–0.81)
0.000079 0.00023 0.0021
rs10276036 TT 26 49%
TC 50 82%
CC 14 100%
per allele C 0.24 0.27 0.42
(0.11–0.47) (0.13–0.54) (0.29–0.81)
0.000079 0.00023 0.0021
*HR: Hazard Ratio.
**Analysis adjusted for metastasis at diagnosis.
doi:10.1371/journal.pone.0026091.t002
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the effect of the vincristine and cyclophosphamide drugs used after
surgery. Since ABCB1 is known to transport vincristine, ABCC3
could also be involved in this process [18,34], and the transport
mechanisms for cyclophosphamide are still unknown, we postulate
that genetic variation in these transporters could play a role in the
effectiveness of the whole treatment and influence the overall
survival.
In conclusion, this study identified four significant SNPs in two
drug transporter genes associated with overall survival in
osteosarcoma patients. After validation in large and well-defined
sets of patients to confirm the associations, these variants could be
useful as prognostic markers in these patients.
Furthermore, the approach used in this study, integrating
multiple drug pathways and studying an increased number of
polymorphisms, may be extended to future pharmacogenetic
studies to provide a wide scenario of genetic factors influencing
drug efficacy and toxicity. The applicability of high-throughput
gene chips that allow simultaneous analysis of multiple polymor-
phisms will facilitate research in this field.
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